XBIT
XBiotech Inc. [XBIT] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
XBIT Stock Summary
In the News
XBIT Financial details
Company Rating
-
Market Cap
281.54M
Income
-24.56M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
82
Optionable
No
Shortable
Yes
Earnings
08 May 2024
P/E
-5.99
Forward P/E
-
PEG
2.4
P/S
461.63
P/B
0.62
P/C
-
P/FCF
-10.68
Quick Ratio
38.44
Current Ratio
38.61
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.81
EPS next Y
-
EPS next Q
-
EPS this Y
-25%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-37.5%
-
-
-
-
SMA20
-1.68%
SMA50
-4.1%
SMA100
-7.87%
Inst Own
-
Inst Trans
-
ROA
-10%
ROE
-10%
ROC
-0.17%
Gross Margin
95%
Oper. Margin
-12362%
Profit Margin
-7708%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3.05-9.96
52W High
-74.33%
52W Low
-23%
RSI
43.86
Rel Volume
0.08
Avg Volume
65.32K
Volume
5.02K
Perf Week
-1.7%
Perf Month
-9.06%
Perf Quarter
-15.07%
Perf Half Y
-17.5%
-
-
-
-
Beta
1.487
-
-
Volatility
0.02%, 0.05%
Prev Close
-1.28%
Price
2.31
Change
-0.43%
Company Profile
- Volume Average 65.32K
- Market Capitalization 281.54M
- Employee 82
- CEO Mr. John Simard
- Headquarters Austin,TX,US
- IPO Date 2015-04-15
-
Website
https://www.xbiotech.com 
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.
